On April 28, Lianhuan Pharmaceutical (600513) announced that its holding subsidiary Lianhuan Marketing officially signed an agreement with Yangzhou High-Tech Zone, planning to invest 300 million yuan to launch the Pharmaceutical Precision Cold Chain Manufacturing Center project.

With the upgrading of compliance requirements in the pharmaceutical industry and the tightening of standards for temperature control and traceability of drugs throughout the entire process, the pharmaceutical cold chain is ushering in a new round of expansion window. Large pharmaceutical companies are stepping up investment in high-standard cold storage, intelligent cold chain warehousing and logistics layout, which has become a standard and necessary requirement in the industry.

This heavy investment in pharmaceutical cold chain infrastructure by Lianhuan Pharmaceutical is not only a comprehensive upgrade of its own warehousing, logistics and temperature-controlled distribution capabilities, but also reflects the industry trend of explosive demand in the pharmaceutical cold chain sector and continuous growth in infrastructure investment, and brings tangible new opportunities for engineering, equipment and system supporting to upstream and downstream enterprises in the refrigeration cold chain industry.

The golden opportunity period for pharmaceutical cold chain has arrived, and the refrigeration industry has broad space to enter this field.